Skip to main content
Clinical Trials/NCT04466839
NCT04466839
Completed
Not Applicable

Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients

University Hospital, Toulouse8 sites in 1 country411 target enrollmentJuly 2, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
University Hospital, Toulouse
Enrollment
411
Locations
8
Primary Endpoint
Impact of containment related to the Covid-19 pandemic.
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease.

These consequences can be assessed by the end of confinement and 6 months after the latter is lifted.

Detailed Description

Adaptation capacities are necessary to cope with the brutal and drastic changes imposed by the pandemic and its consequences. In Parkinson's disease, where there are routine situations with difficulties adjusting to newness, patients in the current situation may be particularly affected and present anxiety due to great difficulties in adaptation. The repercussions in terms of symptoms (motor and non-motor) of the disease could be very significant. In this population already widely exposed to anxio-depressive symptoms (depression being a common symptom of Parkinson's disease, affecting up to 30 to 40% of patients outside of crisis periods), we can expect a risk increased psychiatric decompensation. The psychiatric consequences could not be limited to the current period but also concern long-term patients, in particular if there is decompensation of other symptoms of the disease (motors, complications linked to treatment, etc.). The consequences of COVID-19 in these already fragile patients should be evaluated. It will be important to appreciate the confinement consequences imposed on the patient on the course and impact of the disease. These consequences can be assessed by the end of confinement and 6 months after the latter is lifted. This is an observational, French multicenter study, of an uncontrolled cohort of parkinsonian patients followed by doctors from Parkinson Expert Centers in hospitals.

Registry
clinicaltrials.gov
Start Date
July 2, 2020
End Date
December 18, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient followed by a doctor from the Parkinson Expert Center of the Toulouse University Hospital, Lille, Paris, Rouen, Nimes, Reims, Besancon, Marseille
  • And with idiopathic Parkinson's disease
  • Patients hospitalized or in consultation between 16/03/2020 and 16/05/2020.

Exclusion Criteria

  • Atypical parkinsonian syndrome
  • Patient subject to a legal protection order (tutorship)
  • Patient not wishing to answer questions

Outcomes

Primary Outcomes

Impact of containment related to the Covid-19 pandemic.

Time Frame: 6 months after the end of the pandemic

To compare quality of life using Parkinson Disease Questionnaire-8 Items (PDQ-8 ), during the period of confinement linked to the Covid-19 pandemic and 6 months after the end of the pandemic in patients with idiopathic Parkinson's disease. The minimum value is "never" and maximum value is "always"

Secondary Outcomes

  • The number of patients infected or possibly infected with Covid-19(6 months after the end of the pandemic)
  • Symptoms modifications(6 months after the end of the pandemic)
  • Conditions of containment during the Covid-19 pandemic.(Day 1)

Study Sites (8)

Loading locations...

Similar Trials